PRESS RELEASE
18 April 2017

SyntheticMRs feature REMyDI™, automatic measurement of myelin volume in the brain, is now CE-marked for clinical use in Europe.

REMyDI, first introduced by SyntheticMR AB at the annual RSNA conference in Chicago in 2016, is now CE-marked for clinical use in Europe. Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a unique feature of the SyMRI® post-processing software from SyntheticMR.

Measuring myelin volume with conventional MRI is challenging. With the REMyDI feature in SyMRI, clinicians can now get an automatic volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in less than 10 seconds.

The new feature is now available in the SyMRI NEURO REMyDI package.

SyMRI is compatible with MR scanners from leading vendors. SyMRI is a CE-marked product and is FDA 510(k) pending.

**Rapid Estimation of Myelin for Diagnostic Imaging*

For additional information, please contact Fredrik Jeppsson, CFO and Head of Investor Relations, SyntheticMR AB, +46 76 311 61 14 or Stefan Tell, CEO SyntheticMR AB, +46 73 373 40 90.

SyntheticMR AB *develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single scan. SyMRI is available in three packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps™, parametric T1, T2 and PD maps of the brain, allowing the investigation to be taken even further. SyMRI is a CE-marked product and is FDA 510(k) pending. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com. This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 18 2017.*